High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0190084
Abstract: Background High-dose interleukin-2 (HD IL-2) is used in the treatment of metastatic renal cell carcinoma (mRCC) and has an overall response rate (ORR) of 12–20% and a complete response rate (CR) of 8% in unselected… read more here.
Keywords: renal cell; cell carcinoma; mrcc sarcomatoid; patients mrcc ... See more keywords